MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2018 International Congress

    Advanced Parkinson’s disease Diagnosis and Treatment Trends in Israel – Sub-Analysis of the OBSERVE-PD Multi-Country, Cross-Sectional Study

    R. Djaldetti, S. Hassin-Baer, M. Anca-Herschkovitsch, R. Gross, R. Cohen, H. Banayan, K. Onuk, T. Gurevich (Petah Tikva, Israel)

    Objective: The primary objective of this observational study was to evaluate the proportion of Parkinson’s disease (PD) patients identified as advanced PD (APD) patients according…
  • 2018 International Congress

    Determinants of absence of dyskinesia in Parkinson’s disease patients with treatment beyond 10 years

    R. Ou, Y. Wu, Q. Wei, X. Yuan, Y. Hou, H. Liu, L. Zhang, Y. Chen, B. Cao, X. Chen, H. Shang (Chengdu, China)

    Objective: This study aims to explore the determinants for absence of dyskinesia in patients with Parkinson’s disease (PD) based on a large cohort of Chinese…
  • 2018 International Congress

    STN-DBS causing persistent dyskinetic movements in OFF-State

    J. Muellner, J. Michelis, L. Lachenmayer, K. Petermann, I. Debove (Bern, Switzerland)

    Objective: Transient choreatic movements are known as side effects of DBS of the dorsolateral STN in Parkinson disease (PD). Persistent “brittle” dyskinesia have been reported…
  • 2018 International Congress

    Nonlinearities in outcome-specific hazard of motor and nonmotor long-term complications of Parkinson’s disease

    P. Prange, T. Danaila, C. Laurencin, C. Caire, E. Metereau, H. Merle, E. Broussolle, D. Maucort-Boulch, S. Thobois (Bron, France)

    Objective: To estimate the specific hazard of motor and nonmotor milestones of Parkinson's disease (PD) progression in the long term. Background: Parkinson’s disease greatly varies…
  • 2018 International Congress

    Patients experiencing peak-dose dyskinesia use re-distribution of involuntary movement amplitude throughout their body to minimize the functional impact of dyskinesia

    K. Lebel, E. Goubault, S. Bogard, C. Duval (Montréal, QC, Canada)

    Objective: To investigate the presence of a strategy in dyskinesia amplitude re-distribution enabling patients to perform motor tasks. Background: In Parkinson’s disease (PD), occurrence of…
  • 2018 International Congress

    Absence of wearing-off in Parkinson’s disease patients with treatment beyond 10 years

    Q. Wei, R. Ou, Y. Wu, X. Yuan, Y. Hou, H. Liu, L. Zhang, Y. Chen, B. Cao, X. Chen, H. Shang (Chengdu, China)

    Objective: This study aims to explore the determinants for absence of wearing-off in patients with Parkinson’s disease (PD) based on a large cohort of Chinese…
  • 2018 International Congress

    West Sweden Parkinson Objective Measurement Registry Study (WestPORTS)

    F. Bergquist, A. Ax, A. Sjostrom, S. Wallerstedt (Gothenburg, Sweden)

    Objective: To study a population representative Parkinson’s Disease (PD) patient cohort characterized with objective 6x24h home measurements using the Parkinson Kinetigraph (PKG, Global Kinetics). To…
  • 2018 International Congress

    Levodopa-induced dyskinesia in Parkinson’s disease: Sleep matters

    N. Amato, M. Manconi, J.C. Möller, S. Sarasso, P. Stanzione, C. Städler, A. Kaelin-Lang, S. Galati (Lugano, Switzerland)

    Objective: To investigate the relationship between slow wave activity (SWA) of non-rapid eye movement (NREM) sleep, which underlies adjustment of cortical excitability, and levodopa-induced dyskinesias…
  • 2018 International Congress

    Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease

    M. Bordone, A. Damianich, A. Bernardi, E. Avale, O. Gershanik, J. Ferrario (CABA, Argentina)

    Objective: To genetically abrogate Fyn expression to reduce levodopa induced dyskinesia (LID) in the 6-OHDA mice model of Parkinson’s disease (PD), using intrastriatal-injected lentiviral (LV)…
  • 2018 International Congress

    Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease

    A. Pinna, G. Costa, M. Serra, M. Morelli (Monserrato (CA), Italy)

    Objective: To investigate whether in a model of Parkinson's Disease (PD), an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 40
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley